Hans Hammers, MD PhD

Financial relationships

  • Attribution:
    Self
    Type of financial relationship:
    Grant Or Contract
    Ineligible company:
    BMS
    Date added:
    Date updated:
    02/15/2024
  • Attribution:
    Self
    Type of financial relationship:
    Grant Or Contract
    Ineligible company:
    Merck
    Date added:
    Date updated:
    02/15/2024
  • Attribution:
    Self
    Type of financial relationship:
    Independent contractor
    Ineligible company:
    Pfizer
    Date added:
    Date updated:
    02/15/2024
  • Attribution:
    Self
    Type of financial relationship:
    Independent contractor
    Ineligible company:
    Armo Biosciences
    Date added:
    Date updated:
    02/15/2024
  • Attribution:
    Self
    Type of financial relationship:
    Independent contractor
    Ineligible company:
    BMS
    Date added:
    Date updated:
    02/15/2024
  • Attribution:
    Self
    Type of financial relationship:
    Independent contractor
    Ineligible company:
    Corvus
    Date added:
    Date updated:
    02/15/2024
  • Attribution:
    Self
    Type of financial relationship:
    Independent contractor
    Ineligible company:
    Surface Oncology
    Date added:
    Date updated:
    02/15/2024
  • Attribution:
    Self
    Type of financial relationship:
    Independent contractor
    Ineligible company:
    Merck
    Date added:
    Date updated:
    02/15/2024
Return to 109 DIVISION OF HEM/ONC: ONCOLOGY BOARD REVIEW CONFERENCE "Renal Cancer 1 " (032422)